Misuse of the FDA's humanitarian device exemption in deep brain stimulation for obsessive-compulsive disorder. Academic Article uri icon

Overview

abstract

  • Deep brain stimulation-a novel surgical procedure-is emerging as a treatment of last resort for people diagnosed with neuropsychiatric disorders such as severe obsessive-compulsive disorder. The US Food and Drug Administration granted a so-called humanitarian device exemption to allow patients to access this intervention, thereby removing the requirement for a clinical trial of the appropriate size and statistical power. Bypassing the rigors of such trials puts patients at risk, limits opportunities for scientific discovery, and gives device manufacturers unique marketing opportunities. We argue that Congress and federal regulators should revisit the humanitarian device exemption to ensure that it is not used to sidestep careful research that can offer valuable data with appropriate patient safeguards.

authors

  • Fins, Joseph J
  • Mayberg, Helen S
  • Nuttin, Bart
  • Kubu, Cynthia S
  • Galert, Thorsten
  • Sturm, Volker
  • Stoppenbrink, Katja
  • Merkel, Reinhard
  • Schlaepfer, Thomas E

publication date

  • February 1, 2011

Research

keywords

  • Clinical Trials as Topic
  • Compassionate Use Trials
  • Deep Brain Stimulation
  • Equipment and Supplies
  • Health Services Misuse
  • Obsessive-Compulsive Disorder
  • United States Food and Drug Administration

Identity

Scopus Document Identifier

  • 79955602041

Digital Object Identifier (DOI)

  • 10.1377/hlthaff.2010.0157

PubMed ID

  • 21289352

Additional Document Info

volume

  • 30

issue

  • 2